|
CA2915124C
(en)
|
2001-11-13 |
2018-08-14 |
The Trustees Of The University Of Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
HUE030719T2
(en)
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
|
US9217155B2
(en)
*
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のａａｖベースの治療
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3514232A1
(en)
|
2010-04-23 |
2019-07-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
WO2013006514A2
(en)
*
|
2011-07-01 |
2013-01-10 |
University Of South Florida |
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
|
|
BR112014020325A2
(pt)
*
|
2012-02-17 |
2017-08-08 |
Childrens Hospital Philadelphia |
composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
EP2855684A1
(en)
*
|
2012-05-25 |
2015-04-08 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Vector for the selective silencing of a gene in astrocytes
|
|
CN104704123A
(zh)
*
|
2012-06-21 |
2015-06-10 |
肌肉学研究协会 |
基因治疗载体的广泛的基因递送
|
|
EP3769789A1
(en)
*
|
2012-08-01 |
2021-01-27 |
Nationwide Children's Hospital |
Intrathecal delivery of recombinant adeno-associated virus 9
|
|
US12024568B2
(en)
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
EP2895606A4
(en)
|
2012-09-17 |
2016-07-06 |
Res Inst Nationwide Childrens Hospital |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS (ALS)
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
LT2956477T
(lt)
|
2013-02-15 |
2021-02-10 |
Bioverativ Therapeutics Inc. |
Optimizuotas faktoriaus viii genas
|
|
EP2970946A4
(en)
*
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
|
ES2744833T3
(es)
|
2013-03-14 |
2020-02-26 |
Univ Laval |
Sistema de electrorretinografía (ERG) para la evaluación de trastornos psiquiátricos
|
|
EP3747998B1
(en)
|
2013-03-15 |
2024-07-24 |
The Trustees of the University of Pennsylvania |
Compositions for treating mpsi
|
|
RU2692251C2
(ru)
*
|
2013-05-15 |
2019-06-24 |
Риджентс Оф Зэ Юниверсити Оф Миннесота |
Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
|
|
HUE047996T2
(hu)
|
2013-07-22 |
2020-05-28 |
Childrens Hospital Philadelphia |
AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
|
|
MX373332B
(es)
*
|
2013-07-26 |
2020-05-21 |
Univ Iowa Res Found |
UNA PARTÍCULA rAAV Y UN AGENTE DE INMUNOSUPRESIÓN PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES.
|
|
PL3702466T3
(pl)
|
2013-08-27 |
2023-04-24 |
Research Institute At Nationwide Children's Hospital |
Produkty i sposoby do leczenia stwardnienia zanikowego bocznego
|
|
US9585971B2
(en)
*
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
CA2927366A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
JP2016538276A
(ja)
|
2013-11-05 |
2016-12-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔ Ｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ |
筋萎縮性側索硬化症の処置のためのＮＦ−κＢおよびＳＯＤ−１を阻害する組成物および方法
|
|
US10161011B2
(en)
|
2013-11-29 |
2018-12-25 |
Takara Bio Inc. |
Method for quantifying adeno-associated virus
|
|
DK3081637T3
(da)
*
|
2013-12-11 |
2019-08-12 |
Sumitomo Chemical Co |
Fremgangsmåde til fremstilling af en ciliær marginalzonelignende struktur
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
US10780182B2
(en)
*
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
EP4600255A3
(en)
|
2014-05-02 |
2025-10-22 |
Genzyme Corporation |
Aav vectors for retinal and cns gene therapy
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP3160478A4
(en)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimized factor ix gene
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
CN107106689A
(zh)
*
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
KR102584655B1
(ko)
|
2014-11-14 |
2023-10-06 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
|
RU2727015C2
(ru)
*
|
2014-11-21 |
2020-07-17 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Векторы aav, нацеленные на центральную нервную систему
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
US10450563B2
(en)
|
2015-02-10 |
2019-10-22 |
Genzyme Corporation |
Variant RNAi
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
AU2016229000B2
(en)
*
|
2015-03-10 |
2021-11-04 |
The Trustees Of Columbia University In The City Of New York |
Recombinant Glut1 adeno-associated viral vector constructs and related methods for restoring Glut1 expression
|
|
WO2016172008A1
(en)
*
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
JP7011467B2
(ja)
*
|
2015-05-29 |
2022-02-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ミスフォールドタンパク質の分解のための組成物及び方法
|
|
PT3313991T
(pt)
|
2015-06-23 |
2024-09-27 |
Childrens Hospital Philadelphia |
Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
|
|
ES2895652T3
(es)
*
|
2015-07-07 |
2022-02-22 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
|
|
US10047377B2
(en)
*
|
2015-09-22 |
2018-08-14 |
Loyola University Of Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
US10597655B2
(en)
*
|
2015-09-22 |
2020-03-24 |
Loyola University Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
EP3831842A1
(en)
|
2015-09-28 |
2021-06-09 |
The University of North Carolina at Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017060510A1
(en)
*
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of alzheimer's disease
|
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
WO2017100704A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
PL3411478T3
(pl)
|
2016-02-01 |
2022-10-03 |
Bioverativ Therapeutics Inc. |
Geny zoptymalizowanego czynnika VIII
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
US10973929B2
(en)
|
2016-02-03 |
2021-04-13 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type I
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP4008356A1
(en)
*
|
2016-03-31 |
2022-06-08 |
University of Cincinnati |
Methods and compositions for the treatment of als
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
WO2017181113A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
CN109476707B
(zh)
|
2016-05-13 |
2022-12-02 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
|
RU2758488C2
(ru)
|
2016-05-18 |
2021-10-28 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
|
AU2017268382B2
(en)
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
SG10202100632WA
(en)
*
|
2016-07-26 |
2021-03-30 |
Univ Cornell |
Gene therapy for the treatment of aldehyde dehydrogenase deficiency
|
|
CN110168080B
(zh)
|
2016-08-15 |
2024-05-31 |
建新公司 |
检测aav的方法
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190057110A
(ko)
|
2016-09-28 |
2019-05-27 |
코바, 인크. |
치료적 mots-c 관련 펩타이드
|
|
EP3525583B8
(en)
|
2016-10-12 |
2025-09-10 |
Bioverativ USA Inc. |
Anti-c1s antibodies and methods of use thereof
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CA3042706A1
(en)
|
2016-11-09 |
2018-05-17 |
Intrexon Corporation |
Frataxin expression constructs
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
MA71412A
(fr)
|
2017-04-03 |
2025-04-30 |
Encoded Therapeutics, Inc. |
Expression de transgène sélective d'un tissu
|
|
US10898585B2
(en)
|
2017-04-14 |
2021-01-26 |
Ptc Therapeutics .Inc. |
Gene therapy for AADC deficiency
|
|
AU2018261790B2
(en)
|
2017-05-05 |
2024-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症（ａｌｓ）を処置する方法
|
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP2020526514A
(ja)
|
2017-07-06 |
2020-08-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉ型を治療するための遺伝子治療
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
FI3684423T3
(fi)
|
2017-09-20 |
2023-06-15 |
4D Molecular Therapeutics Inc |
Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
|
|
TWI835747B
(zh)
|
2017-09-22 |
2024-03-21 |
賓州大學委員會 |
用於治療黏多醣病 ii 型之基因治療
|
|
EP3684932A1
(en)
|
2017-09-22 |
2020-07-29 |
Genzyme Corporation |
Variant rnai
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
EP3668997A4
(en)
*
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
CN112501208A
(zh)
|
2017-10-03 |
2021-03-16 |
普利维尔治疗公司 |
用于溶酶体障碍的基因疗法
|
|
BR112020006661A2
(pt)
|
2017-10-03 |
2020-10-13 |
Prevail Therapeutics, Inc. |
terapias de genes para distúrbios lipossomais
|
|
JP7369121B2
(ja)
|
2017-10-11 |
2023-10-25 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体活性を誘発する方法
|
|
US12441998B2
(en)
*
|
2017-10-12 |
2025-10-14 |
The Trustees Of Columbia University In The City Of New York |
SLC2A1 lncRNA as a biologic and related treatments and methods
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
AU2018372235B9
(en)
|
2017-11-27 |
2022-03-10 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and use for inhibiting angiogenesis
|
|
CA3083761A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iiib
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
CN111727259B
(zh)
|
2017-12-01 |
2024-04-19 |
编码治疗公司 |
工程化的dna结合蛋白
|
|
CN112368051A
(zh)
|
2018-03-23 |
2021-02-12 |
马萨诸塞大学 |
用于治疗骨病的基因治疗剂
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
EP3773743A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
EP3780952A4
(en)
|
2018-04-16 |
2022-03-09 |
The Trustees of the University of Pennsylvania |
COMPOSITIONS AND METHODS OF TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
|
US12129476B2
(en)
|
2018-04-27 |
2024-10-29 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of AADC viral vectors
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
MX2020012077A
(es)
|
2018-05-15 |
2021-03-09 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
|
|
EP3802829A4
(en)
|
2018-06-08 |
2022-10-19 |
University of Massachusetts |
ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN CELLS FROM PATIENTS WITH DYSFERLINOPATHY
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US12297241B2
(en)
|
2018-07-06 |
2025-05-13 |
The Regents Of The University Of California |
Method to engineer transplantable human tissues
|
|
EP3820885A4
(en)
|
2018-07-11 |
2022-04-20 |
The Brigham & Women's Hospital, Inc. |
METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
CA3108324A1
(en)
*
|
2018-07-31 |
2020-02-06 |
Cornell University |
Gene therapy methods to control organ function
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
PH12021550254A1
(en)
|
2018-08-03 |
2023-02-06 |
Genzyme Corp |
Variant rnai against alpha-synuclein
|
|
AU2019328337B2
(en)
*
|
2018-08-30 |
2025-04-17 |
Rowan University |
Methods of treating or preventing amyotrophic lateral sclerosis
|
|
KR20210084459A
(ko)
|
2018-09-26 |
2021-07-07 |
캘리포니아 인스티튜트 오브 테크놀로지 |
표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
AU2019354995B2
(en)
|
2018-10-02 |
2024-12-12 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
EP3861113A1
(en)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
EP3861107A1
(en)
|
2018-10-05 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
JP7590968B2
(ja)
*
|
2018-12-05 |
2024-11-27 |
アビオナ・セラピュ―ティクス・インコーポレイテッド |
遺伝子送達のための組み換えアデノ随伴ウイルスベクター
|
|
JOP20210160A1
(ar)
*
|
2018-12-21 |
2023-01-30 |
Univ Pennsylvania |
تركيبات لخفض التعبير عن الجين الناقل بشكل انتقائي لـ drg
|
|
CN113518784A
(zh)
|
2019-01-28 |
2021-10-19 |
科巴公司 |
治疗性肽
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
WO2020174368A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
JP7549360B2
(ja)
|
2019-03-04 |
2024-09-11 |
デューク ユニバーシティ |
網膜症の診断および処置のための組成物および方法
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
KR20210149803A
(ko)
*
|
2019-04-10 |
2021-12-09 |
유니버시티 오브 매사추세츠 |
인자 h 벡터 및 그의 용도
|
|
WO2020210713A1
(en)
|
2019-04-10 |
2020-10-15 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
WO2020210592A1
(en)
*
|
2019-04-12 |
2020-10-15 |
University Of Massachusetts |
Recombinant aav gene therapy for ngyl1 deficiency
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
PH12021552608A1
(en)
*
|
2019-04-29 |
2022-06-20 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
JP2022534733A
(ja)
*
|
2019-05-31 |
2022-08-03 |
ウニベルシダッド アウトノマ デ バルセロナ |
インスリン遺伝子治療
|
|
US20220307024A1
(en)
*
|
2019-06-17 |
2022-09-29 |
Alnylam Pharmaceuticals, Inc. |
Delivery of oligonucleotides to the striatum
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
US20220281922A1
(en)
|
2019-08-02 |
2022-09-08 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
GB2587319A
(en)
*
|
2019-08-12 |
2021-03-31 |
Healing Genes Llc |
Genetic construct
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3151087A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
CN115279896A
(zh)
|
2019-09-30 |
2022-11-01 |
比奥维拉迪维治疗股份有限公司 |
慢病毒载体配制品
|
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
US20220106609A1
(en)
*
|
2019-12-17 |
2022-04-07 |
Nikegen, Llc |
Paravoviral vectors and methods of making and use thereof
|
|
AU2021206256A1
(en)
|
2020-01-10 |
2022-07-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
AU2021213786A1
(en)
|
2020-01-29 |
2022-09-22 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
JP7743075B2
(ja)
|
2020-03-02 |
2025-09-24 |
国立大学法人群馬大学 |
ミクログリア選択的遺伝子発現ベクター
|
|
KR20230003483A
(ko)
|
2020-03-26 |
2023-01-06 |
다이아멘티스 인크. |
망막 신호 데이터를 처리하고 병태들을 식별하기 위한 시스템들 및 방법들
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
GB202005732D0
(en)
*
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
CA3174070A1
(en)
*
|
2020-04-28 |
2021-11-04 |
Pfizer Inc. |
Modified nucleic acids encoding aspartoacylase (aspa) and vectors for gene therapy
|
|
AU2021270447A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions for DRG-specific reduction of transgene expression
|
|
US20230203102A1
(en)
|
2020-05-13 |
2023-06-29 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
MX2023000156A
(es)
|
2020-06-24 |
2023-02-16 |
Bioverativ Therapeutics Inc |
Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina.
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
CN116685329B
(zh)
*
|
2020-08-05 |
2025-03-18 |
杭州嘉因生物科技有限公司 |
核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
|
|
US20230295656A1
(en)
|
2020-08-06 |
2023-09-21 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
EP4240850A1
(en)
*
|
2020-11-04 |
2023-09-13 |
Boehringer Ingelheim International GmbH |
Viral vectors and nucleic acids for use in the treatment of ild, pf-ild and ipf
|
|
US20240050593A1
(en)
*
|
2020-12-18 |
2024-02-15 |
Duke University |
Compositions For and Methods of Enhancing Spinal Cord Tissue Regeneration
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022192708A1
(en)
*
|
2021-03-11 |
2022-09-15 |
Temple University- Of The Commonwealth System Of Higher Education |
Noninvasive aav vectors for highly efficient gene delivery to the nervous system
|
|
MX2023014041A
(es)
|
2021-05-28 |
2023-12-15 |
Shanghai Regenelead Therapies Co Ltd |
Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
|
|
WO2023279108A1
(en)
*
|
2021-07-01 |
2023-01-05 |
Bridgebio Gene Therapy Research, Inc. |
Gene therapy for galactosemia
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4415746A1
(en)
|
2021-10-12 |
2024-08-21 |
Bridgebio Gene Therapy LLC |
Methods and compositions for treating leukodystrophies
|
|
KR20240113624A
(ko)
|
2021-11-02 |
2024-07-22 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드 변이체 및 이의 용도
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4508428A1
(en)
|
2022-04-12 |
2025-02-19 |
Genzyme Corporation |
Dendritic cell assay for innate immunogenicity to gene therapy agents
|
|
AU2023253700A1
(en)
|
2022-04-12 |
2024-11-28 |
Genzyme Corporation |
Use of an irak4 modulator for gene therapy
|
|
KR20250004740A
(ko)
|
2022-04-12 |
2025-01-08 |
젠자임 코포레이션 |
유전자 요법을 위한 irak4 조절제의 용도
|
|
JP2025514794A
(ja)
*
|
2022-04-22 |
2025-05-09 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
ヒト上衣特異的プロモーターおよびその使用方法
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024027632A1
(en)
*
|
2022-08-01 |
2024-02-08 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Novel plasmid backbone to reduce dna impurities in raav preparation
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
KR20250069606A
(ko)
|
2022-09-15 |
2025-05-19 |
보이저 테라퓨틱스, 인크. |
타우 결합 화합물
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025158385A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Pegylated il-2 for suppressing adaptive immune response to gene therapy
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|
|
WO2025235643A1
(en)
|
2024-05-08 |
2025-11-13 |
Genzyme Corporation |
Profiling of gene therapy agents
|